PD-1/CTLA-4 bispecific antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PD-1/CTLA-4 bispecific antibody, covering 2025-05-20 to 2025-05-20. Get the full timeline:
Most recent: Clinical Trial Update: Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis [Phase 1, Phase 2]